文献速递乳腺MR乳腺X线US

非典型导管增生:乳腺动态对比增强MRI可用于减少不必要的开放手术切除

Atypical ductal hyperplasia: breast DCE-MRI can be used to reduce unnecessary open surgical excision.
PubMed 文献 · Eur Radiol · 2020-03-07

回顾性纳入68个经穿刺活检诊断为非典型导管增生(ADH)的病灶(66例女性),术前均行乳腺动态对比增强MRI(DCE-MRI)。DCE-MRI预测恶性升级的敏感度94.1%、特异度60.7%、阳性预测值44.4%、阴性预测值96.8%;若活检区域无可疑强化,可排除大多数恶性。

要点

  • 经穿刺活检诊断ADH后,DCE-MRI活检区域无可疑强化时,可安全排除恶性。
  • DCE-MRI对恶性升级的阴性预测值达96.8%,有助于避免不必要的开放手术。
  • 高级别导管原位癌和浸润性癌在DCE-MRI上均表现为可疑强化,可被识别。

核心结论

  • 经穿刺活检诊断ADH后,若DCE-MRI活检区域无异常强化,可安全排除恶性。
  • 所有升级为高级别导管原位癌和浸润性癌的病例均可在DCE-MRI上识别。
  • 乳腺DCE-MRI可能用于避免超过半数最终良性诊断患者的手术。

研究设计与样本

  • 回顾性研究,纳入2016年1月至2017年12月间经穿刺活检诊断ADH且术前行乳腺DCE-MRI的68个病灶(66例女性)。
  • 两名放射科医师共识解读乳腺X线、超声和MRI图像,以手术切除后最终诊断为参考标准。
  • 比较有无恶性升级患者的临床和影像特征,评估DCE-MRI预测恶性升级的诊断性能。

关键影像表现/征象

  • 17/68(25%)病灶升级为恶性,其中浸润性癌4/17(23.5%),导管原位癌13/17(76.5%)。
  • DCE-MRI上,16/17(94.1%)恶性病灶和20/51(39.2%)良性病灶可见可疑强化。
  • 唯一无可疑强化的恶性病灶为低级别导管原位癌(4 mm)。

诊断标准与关键数值

  • DCE-MRI预测恶性升级的敏感度为94.1%,特异度为60.7%,阳性预测值为44.4%,阴性预测值为96.8%。
  • 其他临床或影像特征在有无恶性升级的患者间均无显著差异。

临床应用与阅片要点

  • 经穿刺活检诊断ADH后,若DCE-MRI活检区域无异常强化,可安全排除恶性。
  • DCE-MRI可能用于避免超过半数最终良性诊断患者的手术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the diagnostic performance of dynamic contrast-enhanced (DCE)-MRI in predicting malignancy after percutaneous biopsy diagnosis of atypical ductal hyperplasia (ADH).

METHODS AND MATERIALS: In this retrospective study, 68 lesions (66 women) with percutaneous biopsy diagnosis of ADH and pre-operative breast DCE-MRI performed between January 2016 and December 2017 were included. Two radiologists reviewed in consensus mammography, ultrasound, and MR images. The final diagnosis after surgical excision was used as standard of reference. Clinical and imaging features were compared in patients with and without upgrade to malignancy after surgery. The diagnostic performance of DCE-MRI in predicting malignant upgrade was evaluated.

RESULTS: A 9-gauge vacuum-assisted biopsy was performed in 40 (58.8%) cases and a 14-gauge core needle biopsy in 28 (41.2%) cases. Upgrade to malignancy was observed in 17/68 (25%) lesions, including 4/17 (23.5%) cases of invasive cancer and 13/17 (76.5%) cases of ductal carcinoma in situ (DCIS). In 16/17 (94.1%) malignant and 20/51 (39.2%) benign lesions, a suspicious enhancement could be recognized in DCE-MRI. The malignant lesion without suspicious enhancement was a low-grade DCIS (4 mm size). Sensitivity, specificity, positive predictive value, and negative predictive value of DCE-MRI on predicting malignancy were respectively 94.1%, 60.7%, 44.4%, and 96.8%. No other clinical or imaging features were significantly different in patients with and without upgrade to malignancy.

CONCLUSION: After a percutaneous biopsy diagnosis of ADH, malignancy can be ruled out in most of the cases, if no suspicious enhancement is present in the biopsy area at DCE-MRI. Breast DCE-MRI may be used to avoid surgery in more than half of the patients with final benign diagnosis.

KEY POINTS: • Breast DCE-MRI can safely rule out malignancy if no suspicious enhancement is present in the biopsy area after a percutaneous biopsy diagnosis of ADH. • All cases of upgrade to high-grade DCIS and invasive cancers can be identified at breast DCE-MRI after a percutaneous biopsy diagnosis of ADH. • Breast DCE-MRI may be used to avoid surgery in more than half of the patients with final benign diagnosis.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Bertani V, Urbani M, La Grassa M, et al. Atypical ductal hyperplasia: breast DCE-MRI can be used to reduce unnecessary open surgical excision. Eur Radiol. 2020. PMID: 32144463. doi:10.1007/s00330-020-06701-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。